Loading…
Disclosed for 41 months, Jan 2014 to Jun 2017. This scheme is no longer reporting.
UTI - Pharma & Healthcare Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In August 2016 it disclosed 26 stocks worth ₹335 Cr, down ₹2.6 Cr from Jul 2016. Its largest positions were Sun Pharmaceutical Industries Limited (22.5%), Dr. Reddy's Laboratories Limited (10.8%), Cipla Limited (9.3%); the ten largest together made up 77.8% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 86.4% of its equity. Cash and debt stood at 1.1%. Compared with Jul 2016 the fund entered 0 new stocks and exited 0.
Top-10 weight is higher than 97% of peers
Holds more stocks than 10% of peers
Holds more cash than 13% of peers
What these mean: concentration · cash
Every line the fund disclosed, with the change against Jul 2016. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 22.46% | down 1.39 pts | ₹75.2 Cr | down ₹5.3 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 10.78% | up 0.62 pts | ₹36.1 Cr | up ₹1.8 Cr | Added |
| Cipla Limited | 9.28% | up 0.80 pts | ₹31.1 Cr | up ₹2.5 Cr | Added |
| Lupin Limited | 8.61% | down 1.42 pts | ₹28.8 Cr | down ₹5 Cr | Trimmed |
| Aurobindo Pharma Limited | 6.34% | up 2.78 pts | ₹21.2 Cr | up ₹9.2 Cr | Added |
| Divi's Laboratories Limited | 5.13% | up 0.52 pts | ₹17.2 Cr | up ₹1.6 Cr | Added |
| Biocon Limited | 4.98% | up 0.51 pts | ₹16.6 Cr | up ₹1.6 Cr | Added |
| Piramal Enterprises Limited | 4.07% | up 0.54 pts | ₹13.6 Cr | up ₹1.7 Cr | Added |
| Alkem Laboratories Limited | 3.41% | down 0.02 pts | ₹11.4 Cr | down ₹14 L | Trimmed |
| Sun Pharma Advanced Research Company Limited | 2.77% | up 0.19 pts | ₹9.3 Cr | up ₹56 L | Added |
| Zydus Lifesciences Limited | 2.45% | up 0.11 pts | ₹8.2 Cr | up ₹30 L | Added |
| IPCA Laboratories Limited | 2.37% | up 0.13 pts | ₹7.9 Cr | up ₹37 L | Added |
| Narayana Hrudayalaya Limited | 2.33% | up 0.16 pts | ₹7.8 Cr | up ₹47 L | Added |
| Syngene International Limited | 1.80% | up 0.22 pts | ₹6 Cr | up ₹70 L | Added |
| Pfizer Limited | 1.73% | up 0.01 pts | ₹5.8 Cr | down ₹2 L | Held |
| Strides Pharma Science Limited | 1.58% | down 0.34 pts | ₹5.3 Cr | down ₹1.2 Cr | Trimmed |
| Sanofi India Limited | 1.53% | down 0.05 pts | ₹5.1 Cr | down ₹20 L | Trimmed |
| Unichem Laboratories Limited | 1.40% | down 0.07 pts | ₹4.7 Cr | down ₹27 L | Trimmed |
| Natco Pharma Limited | 1.25% | up 0.11 pts | ₹4.2 Cr | up ₹34 L | Added |
| GlaxoSmithKline Pharmaceuticals Limited | 1.16% | down 0.10 pts | ₹3.9 Cr | down ₹36 L | Trimmed |
| Cash, TREPS & receivables | 1.13% | down 3.56 pts | ₹3.8 Cr | down ₹12 Cr | Trimmed |
| Indraprastha Medical Corporation Limited | 1.08% | up 0.08 pts | ₹3.6 Cr | up ₹24 L | Added |
| Torrent Pharmaceuticals Limited | 0.69% | up 0.09 pts | ₹2.3 Cr | up ₹27 L | Added |
| DISHMAN PHARMACEUTICALS & CHEMICALS LTD. | 0.64% | up 0.08 pts | ₹2.1 Cr | up ₹24 L | Added |
| Shilpa Medicare Limited | 0.49% | down 0.02 pts | ₹1.6 Cr | down ₹9 L | Trimmed |
| Indoco Remedies Limited | 0.42% | up 0.01 pts | ₹1.4 Cr | up ₹3 L | Added |
| Thyrocare Technologies Limited | 0.13% | up 0.01 pts | ₹45 L | up ₹3 L | Added |
None.
None.
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Compared with
Since Jul 2016, the weight rose most in Finance (+0.4 pts) and Healthcare Services (+0.3 pts), and fell most in Pharmaceuticals (−0.5 pts) and Pharmaceuticals & Biotechnology (−0.2 pts).
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
| Sector | Aug 2015 | Feb 2016 | May 2016 | Jul 2016 | Aug 2016 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 92.0% | 87.7% | 85.2% | 86.6% | 86.4% |
| Healthcare Services | 1.2% | 5.2% | 5.7% | 5.1% | 5.4% |
| Finance | 1.0% | 2.9% | 4.3% | 3.7% | 4.1% |
| Pharmaceuticals | 5.9% | 4.2% | 4.8% | 4.6% | 4.1% |
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.
| 1.6% |
| 1.6% |
| — |
| Jan 2017 | ₹312 Cr | 27 | 0 | 0 | 1.7% | 1.7% | — |
| Dec 2016 | ₹311 Cr | 27 | 1 | 0 | 1.4% | 1.4% | — |
| Nov 2016 | ₹329 Cr | 26 | 0 | 0 | 1.8% | 1.8% | — |
| Oct 2016 | ₹334 Cr | 26 | 0 | 0 | 2.4% | 2.4% | — |
| Sep 2016 | ₹333 Cr | 26 | 0 | 0 | 0.7% | 0.7% | — |
| Aug 2016 | ₹335 Cr | 26 | 0 | 0 | 1.1% | 1.1% | — |
| Jul 2016 | ₹337 Cr | 26 | 0 | 0 | 4.7% | 4.7% | — |
| Jun 2016 | ₹322 Cr | 26 | 0 | 0 | 6.9% | 6.9% | — |
| May 2016 | ₹311 Cr | 26 | 1 | 0 | 6.8% | 6.8% | — |
| Apr 2016 | ₹315 Cr | 25 | 0 | 1 | 7.6% | 7.6% | — |
| Mar 2016 | ₹307 Cr | 26 | 1 | 0 | 7.9% | 7.9% | — |
| Feb 2016 | ₹306 Cr | 25 | 0 | 0 | 11.7% | 11.7% | — |
| Jan 2016 | ₹321 Cr | 25 | 1 | 1 | 9.4% | 9.4% | — |
| Dec 2015 | ₹324 Cr | 25 | 2 | 0 | 10.8% | 10.8% | — |
| Nov 2015 | ₹309 Cr | 23 | 0 | 1 | 12.6% | 12.6% | — |
| Oct 2015 | ₹331 Cr | 24 | 0 | 1 | 9.4% | 9.4% | — |
| Sep 2015 | ₹315 Cr | 25 | 0 | 0 | 10.6% | 10.6% | — |
| Aug 2015 | ₹304 Cr | 25 | 2 | 0 | 10.7% | 10.7% | — |
| Jul 2015 | ₹279 Cr | 23 | 0 | 0 | 9.5% | 9.5% | — |
For any of the 17 earlier months, choose it in “Portfolio as of” at the top of the page.